Welcome to our dedicated page for Meiragtx Holdings Plc SEC filings (Ticker: MGTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MeiraGTx Holdings plc filings document a clinical-stage genetic medicines company with ordinary shares listed on Nasdaq under MGTX. The company’s 8-K reports cover material definitive agreements, collaboration and license arrangements, asset purchases for genetic-medicine programs, Regulation FD clinical disclosures, operating and financial results, and amendments to note and warrant financing arrangements.
Its proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and related corporate-governance disclosures. The filing record also documents capital structure, subsidiary guarantor arrangements, risk-oriented clinical and regulatory disclosures, and program-specific matters involving AAV-hAQP1, AAV-AIPL1, RPGR-related X-linked retinitis pigmentosa assets, and riboswitch technology.
MeiraGTx Holdings plc’s general counsel and secretary, Robert J. Wollin, reported routine equity award activity involving the company’s ordinary shares. On January 7, 2026, one quarter of his restricted share units granted on January 7, 2022 vested, converting 7,500 restricted share units into 7,500 ordinary shares at an exercise price of $0. In connection with this vesting, 4,364 ordinary shares were withheld at a price of $7.73 per share to cover tax obligations. After these transactions, he directly beneficially owned 29,282 ordinary shares of MeiraGTx.
MeiraGTx Holdings plc’s Chief Development Officer Stuart Naylor reported routine equity award activity involving restricted share units and ordinary shares. On January 7, 2026, 37,500 restricted share units vested and converted into the same number of ordinary shares, reflecting one-quarter of an award granted on January 7, 2022. Each restricted share unit converts into one ordinary share upon vesting. To cover tax withholding on this vesting, 17,625 ordinary shares were withheld at a price of $7.73 per share. After these transactions, Naylor directly held 643,166 ordinary shares of MeiraGTx Holdings plc.
MeiraGTx Holdings plc CFO & COO Richard Giroux reported equity compensation activity involving the company’s ordinary shares. On January 7, 2026, 52,500 restricted share units vested, with each unit converting into one ordinary share. As part of the vesting, 28,822 ordinary shares were withheld at a price of $7.73 per share to cover taxes on the award. Following these transactions, Giroux directly beneficially owned 853,172 ordinary shares of MeiraGTx.
MeiraGTx Holdings plc President & CEO and director Alexandria Forbes reported equity award activity in a Form 4. On January 7, 2026, one-quarter of a prior grant of restricted share units vested, converting 62,500 restricted share units granted on January 7, 2022 into the same number of ordinary shares on a one-for-one basis. To cover tax obligations on this vesting, 34,074 ordinary shares were withheld at a price of $7.73 per share. Following these transactions, Forbes directly beneficially owns 1,336,159 ordinary shares of MeiraGTx.
MeiraGTx Holdings plc (MGTX) reported an insider equity transfer by its General Counsel and Secretary. On 11/20/2025, the officer disposed of 5,000 ordinary shares in a transaction reported at a price of $0, using transaction code "G," which indicates a gift. After this transaction, the reporting person directly beneficially owned 26,146 ordinary shares. This filing reflects a change in the insider’s personal holdings and does not describe any operational or financial developments at the company.
MeiraGTx Holdings (MGTX) reported a wider quarterly loss and tighter liquidity. For the three months ended September 30, 2025, total revenue was $410 thousand versus $10.9 million a year ago, driven by lower related-party service revenue. Operating expenses were $46.5 million, leading to a loss from operations of $46.1 million and a net loss of $50.5 million (basic and diluted loss per share $0.62).
Cash and cash equivalents fell to $14.8 million from $103.7 million at year-end, and shareholders’ equity moved to a $(40.6) million deficit as accumulated deficit reached $831.3 million. The company used $93.0 million in operating cash in the first nine months.
Management highlights pending strategic funding: an expected $200 million upfront from Hologen in Q4 2025 (with $28.0 million received during the period and an additional $22.0 million deposit in Q4 to date), up to $230 million of additional Hologen funding, and a $75.0 million upfront from Eli Lilly. Together with tax incentives and receivables, these are expected to fund operations for at least twelve months. Ordinary shares outstanding were 80,490,889 as of October 28, 2025.
MeiraGTx Holdings plc has provided an update on its business by releasing financial results for the quarter ended September 30, 2025. The company issued a press release describing these quarterly results, and that release is being made available as an exhibit to a current report for investors and the market to review.
The press release is furnished as Exhibit 99.1 and, along with the related information, is specifically described as furnished rather than filed, which means it is not automatically subject to certain liability provisions under U.S. securities laws or incorporated into other securities filings unless later specifically referenced. The report is signed on behalf of MeiraGTx by Richard Giroux, the company’s Chief Financial Officer and Chief Operating Officer.
MeiraGTx (MGTX) announced a strategic collaboration and license with Eli Lilly focused on ophthalmology genetic medicines. MeiraGTx will receive an upfront payment of $75 million and is eligible for up to over $400 million in total milestone payments, including up to $135 million tied to development and regulatory milestones. Lilly receives exclusive, worldwide rights to develop and commercialize the AAV-AIPL1 program for LCA4 and two additional preclinical retinal candidates.
Lilly also receives exclusive licenses to proprietary intravitreal capsids and pan‑retinal/rod‑specific promoters for up to five ophthalmology targets each, plus a right of first designation on certain target-specific transactions and a right of first negotiation for MeiraGTx’s riboswitch technology in ophthalmological gene editing. Lilly will fund research, development and commercialization, and MeiraGTx Ocular will receive tiered royalties. The agreement includes standard IP ownership provisions and is terminable for uncured material breach; Lilly may also terminate in whole, by product, or by country with notice.
MeiraGTx Holdings plc (MGTX) reported an insider transaction: CFO & COO Richard Giroux sold 24,000 ordinary shares on Oct 21, 2025 at a $8.87 weighted average pursuant to a Rule 10b5-1 trading plan adopted Aug 29, 2024.
Sale prices ranged from $8.65 to $9.06. After the transaction, he beneficially owns 829,494 shares directly, plus 5,152 indirectly via spouse and 85,000 indirectly via Aigle Healthcare Partners III LLC.
Insider sale by a senior officer: Alexandria Forbes, listed as President & CEO and a director, reported a sale of 47,500 ordinary shares of MeiraGTx Holdings plc (MGTX) on 10/07/2025. The sales were executed under a pre-established Rule 10b5-1 trading plan adopted on 08/21/2024.
The filing shows a weighted average sales price of $8.39, with individual trade prices ranging from $8.23 to $8.53. Following the reported disposition, the reporting person beneficially owns 1,313,983 ordinary shares.